Yes, mirtazapine is FDA-approved and guideline-recommended for treating major depressive disorder.
Mirtazapine is an effective second-generation antidepressant indicated for the treatment of major depressive disorder (MDD) in adults 1. It is explicitly included in the American College of Physicians (ACP) clinical practice guidelines as one of the 12 second-generation antidepressants recommended for treating depressive disorders 2.
Guideline Recommendations
The ACP strongly recommends that when clinicians choose pharmacologic therapy for acute major depression, they should select second-generation antidepressants—including mirtazapine—based on:
- Adverse effect profiles
- Cost
- Patient preferences
This is a strong recommendation with moderate-quality evidence 2.
FDA Approval and Clinical Evidence
Mirtazapine's efficacy was established in 4 placebo-controlled, 6-week trials in adult outpatients with MDD. These studies demonstrated mirtazapine's superiority over placebo on multiple depression rating scales, including the Hamilton Depression Rating Scale (HDRS), Clinical Global Impression (CGI) severity scores, and Montgomery-Asberg Depression Rating Scale (MADRS) 1. The mean effective dose ranged from 21-32 mg/day 1.
Long-term data show that patients who responded to mirtazapine during 8-12 weeks of acute treatment experienced significantly lower relapse rates over 40 weeks compared to placebo 1.
Specific Clinical Advantages
Mirtazapine may offer particular benefits in certain clinical scenarios:
- Faster onset of action: Meta-analysis shows mirtazapine is superior to SSRIs at 2 weeks for both response (RR=1.36) and remission (RR=1.68), though differences disappear by 6-12 weeks 3
- Anxiety symptoms: Mirtazapine slightly outperforms SSRIs for anxiety symptoms in MDD patients 4
- Insomnia: By day 14 at mean dose 18.9 mg/day, 24.8% of patients achieve insomnia remission; by day 42, this increases to 62.4% 5. It is also listed as a sedating antidepressant option for comorbid insomnia 6
- Psychomotor retardation: Presence of psychomotor retardation predicts better response (OR=4.30) 7
Treatment Algorithm
Initial dosing: Start at 15-30 mg at bedtime 6. Titrate based on response, with effective doses typically 21-32 mg/day 1.
Assessment timeline:
- Begin monitoring within 1-2 weeks for therapeutic response and adverse effects 2
- If inadequate response by 6-8 weeks, modify treatment 2
- Continue treatment 4-9 months after satisfactory response for first episode 2
- For patients with ≥2 episodes, consider longer duration 2
Common Pitfalls and Adverse Effects
The most common adverse effects (>10%) include 5:
- Increased appetite and weight gain (most common)
- Somnolence/drowsiness
- Dry mouth
- Headache
- Constipation
- Dizziness
Critical safety consideration: Discontinuation rates due to oversedation occur in 13.2% of patients 7. However, age does not significantly affect tolerability 7.
Metabolic considerations: Women exhibit 18% higher concentration-to-dose ratios, and elderly patients (>65 years) show 27% higher ratios, suggesting need for dose adjustment in these populations 8.
Comparative Effectiveness
At treatment endpoint (6-12 weeks), mirtazapine shows no significant efficacy differences compared to tricyclic antidepressants or SSRIs 3. Total dropout rates due to any reason or side effects are comparable to other antidepressants 3. The choice between mirtazapine and other second-generation antidepressants should therefore prioritize the adverse effect profile, patient preference for sedation versus activation, presence of insomnia or anxiety, and cost considerations 2.